Steba Biotech is focused on the development and launch of ImPACT - Immune Photo Activated Cancer Therapy, a targeted treatment for selective tumor ablation. The company is headquartered in Luxembourg, with divisions in France and Switzerland as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel. Steba biotech holds exclusive rights from the Weizmann Institute of Science (WIS, Israel) and Memorial Sloan Kettering Cancer Center (MSKCC, New York), to develop and commercialize drugs and related technologies used in ImPACT.